Abstract: A housing has a bud portion abutting an elongated stem portion. The bud portion is to fit within an ear. The bud portion has a primary sound outlet at its far end that is to be inserted into an outer ear canal, and abuts the stem portion at its near end. A speaker driver is inside the bud portion. Electronic circuitry inside the housing includes a wireless communications interface to receive audio content over-the-air and in response provides an audio signal to the speaker driver. A rechargeable battery as a power source for the electronic circuitry is located inside a cavity of the stem portion. Other embodiments are also described and claimed.

Abstract: In the compressor of a gas turbine engine, variable guide vanes are adjusted by virtue of connections to an actuation ring that can be rotated within a fixed range of degrees. The connections between the guide vanes and the actuation ring can undergo significant torsional stress. Accordingly, an actuation system is disclosed for reducing the torsional stress experienced by the actuation connections.

Abstract: Methods for detecting patients with eclampsia or preeclampsia by detecting of EDLF in a patient. Methods for screening patients that may be responsive to anti-digoxin antibody therapy are also described. Systems for detecting EDLF include nanowire biosensors.

Abstract: A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment.

Abstract: A method lessening intraventricular hemorrhage in the fetus of a gravid human patient is provided where the patient is administered a therapeutically effective amount of digoxin antibody.

Abstract: A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment.

Abstract: A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity.

Abstract: A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity.

Abstract: A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity.

Abstract: A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity.

Abstract: A method of controlling preeclampsia includes the steps of providing a supply of digoxin immune Fab (ovine), calculating an appropriate dosage of the digoxin immune Fab (ovine) based on a patient's weight and using an assumed endogenous digitalis-like factor level, administering the appropriate dosage as an intravenous bolus, and repeating the administration of the appropriate dosage on a fixed schedule.

Abstract: Revealed is an intelligent camera security monitoring, fuzzy logic analyses and information reporting system that includes video/audio camera, integrated local controller, interfaced plurality of sensors, and input/output means, that collects and analyses data and information observations from a viewed scene and communicates these to a central controller. The central controller with fuzzy logic processor receives, stores these observations, conducts a plurality of computer analyses techniques and technologies including face, voice, lip reading, emotion, movement, pattern recognition and stress analysis to determine responses and potential threat of/by a person, crowd, animal, action, activity or thing. This invention recognizes possible terrorists, criminals, enraged or dangerous persons and also can identify a person's level of intoxication or impairment by alcohol or drugs via a new “Visual Response Measure”.

Abstract: A method of controlling preeclampsia includes the steps of providing a supply of digoxin immune Fab (ovine), calculating an appropriate dosage of the digoxin immune Fab (ovine) based on a patient's weight and using an assumed endogenous digitalis-like factor level, administering the appropriate dosage as an intravenous bolus, and repeating the administration of the appropriate dosage on a fixed schedule.

Abstract: A method of regulating a preeclamptic/eclamptic patient's sodium/potassium ATPase activity includes the administration of digoxin immune Fab (ovine). It is theorized that an endogenous digitalis-like factor present in preeclamptic and eclamptic patients inhibits the functioning of sodium/potassium ATPase, resulting in elevated level of intracellular sodium and calcium levels. These elevated intracellular sodium and calcium levels lead to intravascular volume contraction and vasoconstriction. Digoxin immune Fab (ovine) binds with the endogenous digitalis-like factor to prevent it from interfering with the functioning of the sodium/potassium ATPase, thereby allowing the patient's intracellular sodium and calcium to return to a more normal level.